在小质激活和神经炎症中非编码RNA在阿尔茨海默氏病中
Chunxiang He1,2, Ze Li1,2, Miao Yang1,2
1School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Journal of inflammation research
|September 27, 2023
概括
非编码RNAs (ncRNAs) 通过向基因和调节炎症来调节阿尔茨海默病 (AD) 中的微质激活. 需要进一步的研究来了解潜在的AD治疗的ncRNA机制.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,由粉样质斑块和神经纤维状结形成.
- 微质激活与AD病理和神经炎症密切相关.
- 非编码RNAs (ncRNAs) 是细胞功能的关键调节者,包括微质激活.
研究的目的:
- 审查ncRNAs在微质激活和蛋白质表达中的调节作用.
- 探索ncRNAs如何调节炎症路径,并为AD中的神经炎症做出贡献.
- 突出了解微质的ncRNA调节的复杂性和目前的局限性.
主要方法:
- 文献综述侧重于ncRNAs,微质激活和阿尔茨海默病.
- 对ncRNA与基因,蛋白质和炎症途径相互作用的分析.
- 综合目前关于ncRNA介导微质功能调节的研究.
主要成果:
- ncRNAs直接向基因和蛋白质,影响AD中的微质激活和炎症反应.
- ncRNAs调节炎症通路,影响炎症因素的表达.
- 关于微质偏向 (M1/M2表型) 的ncRNA调节存在重大争议和知识差距.
结论:
- ncRNAs在调节微质激活和阿尔茨海默病中神经炎症方面发挥着重要作用.
- 目前对微质功能中的ncRNA机制的理解尚不完整,需要进一步研究.
- 基于ncRNA的疗法为阿尔茨海默病治疗提供了一个有前途的新途径.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
01:22MicroRNAs
21.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.4K
01:26Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212